Dyne Therapeutics elects Carlo Incerti, M.D. to Board of Directors

Dyne Therapeutics, Inc.

Dr. Incerti elected as Class I director, term expiring at 2024 annual meeting.
Received option to purchase 39,139 shares at $8.69 per share (March 2 closing price).
Option vests in equal monthly installments over three years; full acceleration on change of control.
Annual cash compensation of $35,000 plus standard director equity grants and expense reimbursement.
Board determined Dr. Incerti is an independent director under Nasdaq rules.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Carlo Incerti

Director

DYN · Dyne Therapeutics, Inc.

Effective: 2022-03-02
Filed: March 3, 2022, 6:59 PM ET

On March 2, 2022, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Carlo Incerti, M.D. as a Class I director to serve on the Board until the Company’s 2024 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Carlo Incerti was elected as Director at Dyne Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

On March 2, 2022, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Carlo Incerti, M.D. as a Class I director to serve on the Board until the Company’s 2024 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.

View on SEC.gov

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-002731

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.